研究证实DecisionDx-黑色素瘤测试有效预测黑色素瘤SLN阳性风险,可能减少不必要的手术. Study confirms DecisionDx-Melanoma test effectively predicts melanoma SLN positivity risk, potentially reducing unnecessary surgeries.

世界外科瘤学杂志的一项研究证实,Castle Biosciences的DecisionDx-Melanoma测试可以有效预测黑色素瘤患者的哨戒淋巴结 (SLN) 阳性风险. A study in the World Journal of Surgical Oncology confirms that Castle Biosciences' DecisionDx-Melanoma test can effectively predict sentinel lymph node (SLN) positivity risk in melanoma patients. 通过对肿瘤生物学和临床因素进行评估,测试辅助工具能够对SLNB作出更知情的决定,从而可能减少不必要的手术。 By assessing tumor biology alongside clinical factors, the test aids in making more informed decisions about SLNB, potentially reducing unnecessary surgeries. 对156名病人的分析表明,没有被归类为低风险的病人有正的SLN,表明低风险病例的SLNB下降了33%。 The analysis of 156 patients showed that none classified as low-risk had positive SLNs, suggesting a 33% reduction in SLNB for low-risk cases.